INTRODUCTION

First described by James Parkinson and then characterized by Jean-Martin Charcot, the Parkinson Disease (PD) has several symptoms as resting tremor, rigidity, bradykinesia and postural problems1. The classic clinical picture of PD can be divided into two basic types (clinical): the akinetic-rigid, characterized by the presence of akinesia and/ or rigidity, and the hyperkinetic, present only in tremors2.

Besides the motor symptoms, different studies showed the frequent existence of dysphagia during the PD evolution not always associated to it3-5. Dysphagia is a symptom related to any change when swallowing, hampering secure, efficient and comfortable oral ingestion6. Its exact prevalence in PD is unknown, but estimations ranges from 18 to 100%5.

The physiopathology of swallowing changes are still controversial, some authors associate the changes found with the bradykinesia and others...
authors associate it with rigidity\(^7\). These symptoms are result of degeneration of black substance of the midbrain and consequently diminution of dopamine\(^8\).

Dopamine reposition is the main treatment of PD and it is done through the use of Levodopa, a therapy very efficiency for the improvement of symptoms and it is considered a pattern when compared to other medicine\(^9\)-\(^11\). However, the specific neural changes caused for this medicine improving the motor function are not clear\(^12\). This brings controversies in the swallowing abnormality in PD\(^13\).

Within the instrumental examinations used in the swallowing evaluation, there is the Surface Electromyography (EMGs) as a simple, reproducible, not invasive technic of low discomfort level during the examination giving important data for the evaluation of swallowing parameters. It enables to measure the muscle activity collected through surface electrodes put in the muscle skin\(^14,15\).

In this way, the objective of this study is to evaluate the swallowing electromyography parameters of different clinical PD types in on and off phases.

### METHODS

It is an analytic study, longitudinal type, observing Levodopa action compared between swallowing on and off phases of clinical PD types.

This study was approved by the Ethic Committee in Research with Human Beings of the Health Science Center of the Federal University of Pernambuco (UFPE), n°368/2010 – CEP/CCS. All participants were informed of the objective signing the free and clarify consent term.

The study was performed in the Pro-Parkinson Program of the Clinic Hospital of the Federal University of Pernambuco (HC/UFPE) together with the Pro-Parkinson Extension Project: Speech Therapy linked to Pro-Parkinson Program. The program is multidisciplinary and attend patients with PD arriving at the hospital with a doctor routine follow up. Twenty-six patients with clinical idiopathic PD diagnosis were chosen, proven by the Neurologist of the Pro-Parkinson Program.

In the research, subjects with craniofacial abnormalities or injuries in speech articulation organs; associated neurological disorder; decompensated systemic diseases; total absence of teeth; without the use of dental prosthesis, poorly fitting prosthesis; compromised cognitive level (identified by the Mini Mental State Examination - MMSE); in use of alternative ways to diet; subject to imminent risk of aspiration, demonstrating weak and ineffective cough and classified in stages 4 and 5 according to the scale original version of “Hoehn & Yarh” (HY)\(^16\) and who did not take Levodopa.

The study population were 20 patients with idiopathic PD. There were 6 losses because of the bad fitting prosthesis, parkinsonism induced by drugs, other neurological disorders associated with cognitive retardation patient identified by the MMSE, strong dysarthria with exaggerated tongue movement and not able to complete the exam.

The stage classification of the disease according to the HY scale observed four patients in stage 1, eight in stage 2 and eight in stage 3.

In PD, patients have predominantly tremor have higher average of age, disease duration, duration of medication and daily dose of Levodopa, following then by rigid-akinetic and mixed group respectively (Table 1).

<table>
<thead>
<tr>
<th>CLINICAL TYPE</th>
<th>N</th>
<th>AGE (Years old)</th>
<th>GENDER (M/F)</th>
<th>TIME OF THE DISEASE (years)</th>
<th>MEDICATION TIME (Years)</th>
<th>LEVODOPA (mg / day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tremor</td>
<td>6</td>
<td>68±10</td>
<td>3/3</td>
<td>8±3.1</td>
<td>7±4.3</td>
<td>688±190</td>
</tr>
<tr>
<td>Rigid/akinetic</td>
<td>9</td>
<td>57±11</td>
<td>7/2</td>
<td>4±2.8</td>
<td>4±2.2</td>
<td>611±176</td>
</tr>
<tr>
<td>Mixed</td>
<td>5</td>
<td>59±7*</td>
<td>5/0</td>
<td>3±1.2</td>
<td>3±1.4</td>
<td>340±114</td>
</tr>
<tr>
<td>Total</td>
<td>20</td>
<td>60±10</td>
<td>15/5</td>
<td>5±3.3</td>
<td>4±3.3</td>
<td>566±211</td>
</tr>
</tbody>
</table>

PD: Parkinson disease; N: number; M/F: Male/Female; mg/day: miligram a day.
Swallowing in Parkinson’s Disease

For data collection, the research was divided into two stages: first the PD patients confirming clinical diagnosis, disease stage (HY) and they answered the questions of the data record where the eligibility criteria were observed.

Item III of the Unified Parkinson’s Disease Rating Scale - UPDRS17 on the motor examination was used to verify the predominant symptom. With three groups patients with tremor, patients with predominant rigidity (or bradykinesia) and patients who had the symptoms of tremor and rigidity (or bradykinesia) similarly.

The swallowing start was considered when the EMG activity increased activity clearly above the previous base. The end of swallowing was scored when the EMG activity levels returned to base activity. The difference between the beginning and the end of swallowing determines the duration of the EMG activity during swallowing.

The records were saved as text files (.txt) so they could be read by EMG BioanalyzerBR (version 1.0) to perform the data analysis obtained through the EMG19.

The studied variables were: number of swallows in parts (or multiple), duration (in seconds) and amplitude (through the root mean square - RMS average) of swallowing, which are continuous quantitative variables. Data were tabulated in Microsoft Excel spreadsheets and the results were presented as mean (±) patterns deviation and percentages.

Following the prerequisites, the Shapiro-Wilk and Kolmogorov-Smirnov test showed that the amplitude and number of swallows in parts variables opposed to duration variables were not normally distributed, so the comparison of these variables between the on and off phases of the types clinical PD was performed using the Kruskal Wallis test.

The comparison of the duration of swallowing variable was performed using ANOVA test. As level of statistical significance p <0.05 was considered. Data were analyzed through the statistical program Statistical Package for TM Social Sciences, version 19.0 (SPSS).

RESULTS

Swallowing in parts:

In off codification, the presence of swallowing in parts in at least one of the volumes and consistencies offered, was high in the three groups evaluated, being a little bigger in the group of rigid-akinetic patients (56% to 67%), followed by tremors (33% to 67%) and mixed (40% to 60%).

After the use of Levodopa, phase on, percentages of rigid-akinetic patients with swallowing in parts decreases for all the volumes and consistencies. In the group of tremors there was also decrease the swallowing in parts with water, being similar with yogurt. The mixed group showed decrease in swallowing in parts with 3ml of water and 10 ml of yogurt, being equal to the others (Table 2).
Table 2 - Percentage of the subjects of each clinical type with swallowing in parts in the on and off phases

<table>
<thead>
<tr>
<th>Consistency</th>
<th>Volume (ml)</th>
<th>Tremor (off)</th>
<th>Rigid/akinetic (off)</th>
<th>Mixed (off)</th>
<th>Tremor (on)</th>
<th>Rigid/akinetic (on)</th>
<th>Mixed (on)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Water</td>
<td>3</td>
<td>67%</td>
<td>56%</td>
<td>40%</td>
<td>33%</td>
<td>44%</td>
<td>40%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>50%</td>
<td>56%</td>
<td>40%</td>
<td>33%</td>
<td>44%</td>
<td>40%</td>
</tr>
<tr>
<td>Yogurt</td>
<td>3</td>
<td>33%</td>
<td>56%</td>
<td>40%</td>
<td>33%</td>
<td>56%</td>
<td>40%</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>50%</td>
<td>67%</td>
<td>60%</td>
<td>50%</td>
<td>60%</td>
<td>40%</td>
</tr>
</tbody>
</table>

ml: milliliter.

When the average swallowing in parts for water is analyzed, in off phase, despite the rigid-akinetic patients present higher average in swallowing 10 ml of water, there was not significant difference among the groups for any of the volumes.

In the on phase of clinical types, the group of rigid-akinetic patients presented higher decrease in the average of swallowing in parts, in the group of tremors there was a small decrease and in the mixed group were the same average for swallowing water volume. However, there were not significant differences between phase on and off in none of the groups.

In the off phase, the average of the number of swallowing in parts of each clinical type, there were again higher in the rigid-akinetic group, however there was no significant difference among the groups.

After the medication, only the rigid-akinetic group showed reduction in the average of swallowing in parts. The other groups of clinical type kept similar average before and after the medication (Figure 1).

![Figure 1 - Average of number of swallowing in parts of 3 ml and 10 ml of water and yogurt in the clinical type of Parkinson disease in on and off phase.](image)

PD: Parkinson disease; ml: milliliters. *p ≤0.05 (Teste Kruskal Wallis).
sEMG Amplitude:

In the off phase of PD clinical types, the average of the sEMG amplitudes of swallowing of 3 ml and 10 ml of water was lower in the mixed patients group, the rigid-akinetic and tremors groups showed similar averages.

In the medication effect, all groups showed small elevation of the sEMG amplitudes, especially the rigid-akinetic group. However, there was no significant difference among the groups.

As well as in the swallowing of water, in off phase, sEMG amplitudes of swallowing of yogurt were less in the mixed group. The other group has equal amplitudes.

In the on phase, all group presented small elevation of the amplitudes, however the mixed group continue presenting lower values. These differences were not significant statistically (Figure 2).

Duration of sEMG:

When checking the duration of sEMG of swallowing water, both the off and on condition, the rigid-akinetic group present electrophysiological activity slightly longer than the tremor and mixed.

After the medication, time of sEMG did not suffer big changes in none of the groups, with no significant differences.

The duration of the sEMG in swallowing yogurt was also higher in the rigid-akinetic group, followed by the mixed group, before and after Levodopa.

In the on phase, the mixed group showed little decrease in the duration of sEMG of volumes of 3 ml and 10 ml, while tremor and rigid-akinetic reduced the time in swallowing of 3 ml of yogurt and increased the time swallowing 10 ml. However, all the differences were small and not significant (Figure 3).
DISCUSSION

The rigid-akinetic group in off phase, showed the highest number of patients with swallowing in parts, as well as higher average in swallowing in parts. The duration of EMGs of this clinical type was also a bit longer than the other groups. These findings indicate an impairment in swallowing of these patients because any duplication or swallowing multiplication with less than or equal to 20 ml of water (dysphagia limit) volumes, is considered pathological20.

In this way, the higher duration of EMGs may be related with bradykinesia, and/or incoordination of the muscles involved in swallowing process of PD patients15. Adaptive lack of mechanisms to create space in the oral cavity was observed in patients with PD, and it is interpreted as a form of hypokinesia21. The prolongation of the transit time of oro-pharyngeal is a data that reflects most consistently the dysfunction caused by the rigidity and hypokinesia22.

On the other hand, in this study although not significant, the rigid-akinetic group seem to have a better response to therapy with Levodopa, since in the on phase, little changes occurred as: reduction in the percentage of patients with swallowing in parts, lower average in swallowing in parts, increased amplitudes and reduction duration of EMGs.

When bradykinesia is predominant, treatment with Levodopa is useful and the symptom disappears in a short time because this symptom would be directly related to symptom reduction of dopamine23. The administration of single doses of Levodopa reduces the rigidity of patients with DP24.

The tremor group of patients in off phase has generally similar to the values of the other groups. That is, when considering the average of swallowings in parts and the duration of the EMGs, tremors have values similar to those observed in the mixed group. When the scope is analyzed, tremor group shows similar values to those observed in rigid-akinetic group.

After using the medication, changes of the tremor group were minimal, which agrees with other authors when they state that nigrostriatal degeneration is very related to bradykinesia and rigidity than tremor. The mechanism of subthalamic stimulation and pallidotomy show a better response to the treatment of tremor than for the other two symptoms25.

However, there are reports that surgical interventions such as pallidotomy, thalamotomy, and deep brain stimulation have no positive effects on swallowing function, with worsening dysphagia often cited as a complication of surgical interventions26.

It is noteworthy that the average age and duration of disease higher in predominantly tremulous group may indicate a longer life expectancy, thus strengthening claims of some authors16,27,28 that the PD would present earlier with slower progression and better prognosis in this clinical type of disease. However, despite the rigid-akinetic group presents a slightly bigger loss than tremor in some of the electrophysiological parameters, there were no significant differences between groups.

The mixed group was highlighted because it had lower EMGs amplitudes than the other groups, which may indicate that the association of rigidity/bradykinesia, more tremor symptoms can bring greater harm to the activation of muscles, but no significant difference. After the use of Levodopa, mixed patients had a small increase in amplitude,
which remained lower than the other groups, although not significant, too.

The scarcity of electrophysiological studies that address the effect of Levodopa in the types of clinical swallowing in PD makes difficult comparison of results.

In a study using videofluoroscopy (VF) as an evaluation tool, patients were separated into tremor and non-tremor. The author states not finding significant differences between the groups and that generally half of patients improved on the on phase, the author assuming that occurred due to decreased bradykinesia and rigidity of the tongue.29

Another author also used the VF, to verify the differences between dyskinetic and non-dyskinetic patients, concluding that dyskinetic patients have a higher efficiency of oropharyngeal swallowing, which can be explained by higher doses of Levodopa. The author also suggests that other neurotransmitter systems in addition to dopamine are involved in swallowing disorders in PD 13.

Other studies also raise questions about PD constitute a single disease entity. These doubts are fed by clinical heterogeneity, suggesting at least two different clinical forms: PD tremor and PD rigid-akinetic.

**CONCLUSIONS**

Medicine therapy through Levodopa has not shown consistent differences in electromyographic parameters of swallowing between clinical types of PD.

However, due to the large interindividual variability, it is suggested to conduct further studies with larger sample.

**ACKNOWLEDGEMENT**

To Conselho Nacional de Desenvolvimento Científico e Tecnológico – CNPq
To Núcleo de Atenção ao Idoso – NAI/UFPE
To Programa Pró-Parkinson do HC/UFPE

---

**RESUMO**

**Objetivo:** avaliar os parâmetros eletromiográficos da deglutição dos diferentes tipos clínicos da doença de Parkinson idiopática nas fases on e off. **Métodos:** foram estudados 20 pacientes com doença de Parkinson, divididos através da Escala Unificada de Avaliação da Doença de Parkinson em três grupos: tremulantes, rígido-acinético e misto. O exame de eletromiografia de superfície foi coletado sobre a musculatura supra-hióidea durante a deglutição de 3 ml e 10 ml de água e iogurte, que foi repetida 5 vezes para cada volume e consistência. Este protocolo foi realizado no antes e após a medicação, período off e on. **Resultados:** verificou-se que na fase off, o grupo rígido-acinético apresentou as maiores médias de deglutições em partes e duração das eletromiografias de superfície, enquanto que o grupo misto apresentou as menores médias de amplitude. Na fase on, os três grupos tenderam a melhorar ou manter as médias das variáveis estudadas, porém não houve diferença significante entre os tipos clínicos, antes ou depois da Levodopa. **Conclusão:** a terapia medicamentosa através da Levodopa não apresenta diferenças consistentes nas eletromiografias de superfície da deglutição dos tipos clínicos da doença de Parkinson.

**DESCRITORES:** Doença de Parkinson; Deglutição; Transtornos da Deglutição; Eletromiografia; Levodopa
REFERENCES